Corient Private Wealth’s Genmab GMAB Stock Holding History

Corient Private Wealth’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$436K	Sell	16,647 -18,291	-52%	-$548K	﹤0.01%	2104
2025 Q4	$1.07M	Buy	34,938 +19,193	+122%	+$598K	﹤0.01%	1849
2025 Q3	$483K	Buy	+15,745	New	+$384K	﹤0.01%	1808
2025 Q2	–	Sell	-20,548	Closed	-$402K	–	2482
2025 Q1	$402K	Buy	+20,548	New	+$431K	﹤0.01%	1705
2024 Q4	–	Sell	-10,505	Closed	-$256K	–	2418
2024 Q3	$256K	Buy	10,505 +22	+0.2%	+$588	﹤0.01%	2092
2024 Q2	$263K	Buy	+10,483	New	+$297K	﹤0.01%	1983
2023 Q4	–	Sell	-9,020	Closed	-$318K	–	2283
2023 Q3	$318K	Buy	9,020 +595	+7%	+$22.7K	﹤0.01%	1728
2023 Q2	$320K	Buy	8,425 +293	+4%	+$11.7K	﹤0.01%	1665
2023 Q1	$307K	Buy	+8,132	New	+$313K	﹤0.01%	1596

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Corient Private Wealth's GMAB Position: Q1 2026 in Review

Corient Private Wealth reduced its Genmab (GMAB) stake by 52% in Q1 2026, selling an estimated $548K and leaving 16,647 shares worth $436K. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

Corient Private Wealth first reported a position in GMAB in Q1 2023 and has held it in 9 quarters since. The position peaked at $1.07M in Q4 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Corient Private Wealth held 16,647 shares of Genmab worth $436K as of Q1 2026.
Corient Private Wealth sold 18,291 Genmab shares in Q1 2026, an estimated $548K.
Genmab made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2104 holding.
Corient Private Wealth first reported a position in Genmab in Q1 2023 and has held it in 9 quarters since.
Corient Private Wealth's Genmab position peaked at $1.07M in Q4 2025.
272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.